Communities & Collections
Researchers & Labs
Titles
DGIST
LIBRARY
DGIST R&D
Detail View
Department of New Biology
Biointerface Structure and Skin Lab
1. Journal Articles
Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy
Mariadoss, Arokia Vijaya Anand
;
Sivakumar, Allur Subramaniyan
;
Lee, Chang-Hun
;
Kim, Sung Jae
Department of New Biology
Biointerface Structure and Skin Lab
1. Journal Articles
Citations
WEB OF SCIENCE
Citations
SCOPUS
Metadata Downloads
XML
Excel
Title
Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy
Issued Date
2022-07
Citation
Biomedicine and Pharmacotherapy, v.151
Type
Article
Author Keywords
Diabetic foot ulcer
;
Diabetes mellitus
;
Metabolic disorders
;
Insulin receptors
;
Glucose transporters
;
Nanomedicine
Keywords
GLYCOPROTEIN COMPONENTS
;
INSULIN-RESISTANCE
;
ISLET NEOGENESIS
;
DRUG-DELIVERY
;
RISK-FACTOR
;
NANOPARTICLES
;
THERAPY
;
EFFICACY
;
NANOSUSPENSION
;
SULFONYLUREAS
ISSN
0753-3322
Abstract
Diabetes mellitus (DM) is a collection of metabolic and pathophysiological disorders manifested with high glucose levels in the blood due to the inability of β-pancreatic cells to secrete an adequate amount of insulin or insensitivity of insulin towards receptor to oxidize blood glucose. Nevertheless, the preceding definition is only applicable to people who do not have inherited or metabolic disorders. Suppose a person who has been diagnosed with Type 1 or Type 2DM sustains an injury and the treatment of the damage is complicated and prolonged. In that case, the injury is referred to as a diabetic foot ulcer (DFU). In the presence of many proliferating macrophages in the injury site for an extended period causes the damage to worsen and become a diabetic wound. In this review, the scientific information and therapeutic management of DM/DFU with nanomedicine, and other related data were collected (Web of Science and PubMed) from January 2000 to January 2022. Most of the articles revealed that standard drugs are usually prescribed along with hypoglycaemic medications. Conversely, such drugs stabilize the glucose transporters and homeostasis for a limited period, resulting in side effects such as kidney damage/failure, absorption/gastrointestinal problems, and hypoglycemic issues. In this paper, we review the current basic and clinical evidence about the potential of medicinal plants, gene therapy, chemical/green synthesized nanoparticles to improving the metabolic profile, and facilitating the DM and DFU associated complications. Preclinical studies also reported lower plasma glucose with molecular targets in DM and DFU. Research is underway to explore chemical/green synthesized nanoparticle-based medications to avoid such side effects. Hence, the present review is intended to address the current challenges, recently recognized factors responsible for DM and DFU, their pathophysiology, insulin receptors associated with DM, medications in trend, and related complications. © 2022
URI
http://hdl.handle.net/20.500.11750/16921
DOI
10.1016/j.biopha.2022.113134
Publisher
Elsevier
Show Full Item Record
File Downloads
There are no files associated with this item.
공유
공유하기
Related Researcher
Lee, Chang-Hun
이창훈
Department of New Biology
read more
Total Views & Downloads